GSK granted option on pneumococcal vaccine proteins
This article was originally published in Scrip
The Israeli start-up Protea Vaccine Technologies has entered a collaboration and option agreement that grants GlaxoSmithKline Biologicals the option to obtain an exclusive licence to a set of Protea’s conserved pneumococcal proteins for the development and commercialisation of a universal protein-based Streptococcus pneumoniae vaccine. Protea is affiliated with another Israeli vaccine firm NasVax.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.